| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 47.430 | 46.671 | 45.213 | 45.940 | 49.797 | 52.259 | 65.288 | 81.547 | 82.305 |
| Total Income - EUR | 0 | 47.430 | 47.400 | 45.213 | 45.940 | 50.317 | 52.259 | 72.046 | 81.768 | 82.349 |
| Total Expenses - EUR | 19 | 26.247 | 32.649 | 30.589 | 28.691 | 24.911 | 25.440 | 26.967 | 46.829 | 45.771 |
| Gross Profit/Loss - EUR | -19 | 21.184 | 14.751 | 14.625 | 17.249 | 25.405 | 26.819 | 45.079 | 34.938 | 36.578 |
| Net Profit/Loss - EUR | -19 | 17.487 | 12.176 | 14.173 | 16.326 | 24.080 | 25.602 | 43.388 | 30.102 | 30.796 |
| Employees | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Monovia Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 134 | 0 | 15.638 | 11.513 | 7.527 | 5.951 | 3.687 | 3.234 | 33.238 | 28.762 |
| Current Assets | 45 | 22.812 | 3.761 | 5.422 | 10.618 | 19.821 | 24.351 | 43.282 | 21.850 | 31.060 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 4.364 | 3.634 | 3.868 | 3.793 | 4.734 | 4.629 | 32.049 | 19.978 | 28.555 |
| Cash | 45 | 18.448 | 127 | 1.554 | 6.825 | 15.087 | 19.722 | 11.232 | 1.872 | 2.506 |
| Shareholders Funds | 26 | 17.513 | 12.318 | 14.728 | 16.376 | 24.130 | 25.651 | 43.505 | 30.250 | 30.860 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 153 | 5.299 | 7.081 | 2.207 | 1.769 | 1.643 | 2.387 | 3.011 | 24.838 | 28.963 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7020 - 7020" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Monovia Pharm Srl